Study indicates potential danger from aspirin/hormone therapy mix

WALTHAM, Mass. A letter published in the Dec. 27 issue of the New England Journal of Medicine reported that men undergoing hormone therapy for prostate cancer may need to stop supplementing with 81 mg aspirin, which in addition to its reputation for helping reduce the risk of heart disease has also been linked to prevention of prostate cancer.

According to published reports, aspirin interacts with the hormone therapy to elevate liver-function test levels. Hormone therapy is typically suspended when liver-function is elevated, and men with prostate cancer who are not on hormone therapy have a higher mortality rate.